72985-19-4

Upstream product

• 118-90-1 ortho-methylbenzoic acid 
• 50-00-0 formaldehyd 
• 478977-50-3 tert-butyl 5-(bromomethyl)-2-methylbenzoate 

Downstream Products

• 1044872-03-8 C₂₈H₃₈N₂O₃Si 
• 1044872-02-7 C₁₄H₂₀N₂O₂ 
• 924300-41-4 5-(bromomethyl)-N,2-dimethylbenzamide 
• 1044870-27-0 3-(4-hydroxy-3,5-dimethylphenyl)-7-(morpholinomethyl)isoquinoline-1(2H)-one 
• 1044872-01-6 C₉H₈BrClO 
• 522632-91-3 2-Methyl-5-[(2R,3R,4S,5R,6S)-4,5,6-tris-benzyloxy-3-(4-oxo-pentanoyloxy)-tetrahydro-pyran-2-ylmethoxymethyl]-benzoic acid (2R,4aR,6S,7R,8S,8aR)-7-benzyloxy-6-ethylsulfanyl-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 522633-05-2 5-[(2R,3R,4S,5R,6S)-4,5-Bis-benzyloxy-6-methoxy-3-(4-oxo-pentanoyloxy)-tetrahydro-pyran-2-ylmethoxymethyl]-2-methyl-benzoic acid (2R,4aR,6S,7R,8S,8aR)-7-benzyloxy-6-ethylsulfanyl-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 522632-92-4 2-Methyl-5-((2R,3R,4S,5R,6S)-4,5,6-tris-benzyloxy-3-hydroxy-tetrahydro-pyran-2-ylmethoxymethyl)-benzoic acid (2R,4aR,6S,7R,8S,8aR)-7-benzyloxy-6-ethylsulfanyl-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 522632-93-5 benzyl 6,3'-O-(2-methyl-5-methylene-benzoyl)-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1 - 4)-2,3-di-O-benzyl-α-D-glucopyranoside 
• 522633-06-3 5-((2R,3R,4S,5R,6S)-4,5-Bis-benzyloxy-3-hydroxy-6-methoxy-tetrahydro-pyran-2-ylmethoxymethyl)-2-methyl-benzoic acid (2R,4aR,6S,7R,8S,8aR)-7-benzyloxy-6-ethylsulfanyl-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-8-yl ester 
• 522633-08-5 methyl O-(2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(1 - 4)-2,3-di-O-benzyl-6-O-(3-methoxycarbonyl-4-methylbenzyl)-α-D-glucopyranoside 
• 522633-07-4 methyl 6,3'-O-(2-methyl-5-methylenebenzoyl)-2-O-benzyl-4,6-O-benzylidene-β-D-glucopyranosyl-(1 - 4)-2,3-di-O-benzyl-α-D-glucopyranoside 
• 522632-88-8 tert-butyl 5-[benzyl 2,3-di-O-benzyl-4-O-(4-methoxybenzyl)-α-D-glucopyranosid-6-yloxymethyl]-2-methylbenzoate 
• 522632-89-9 tert-butyl 5-(benzyl 2,3-di-O-benzyl-4-O-levulinoyl-α-D-glucopyranosid-6-yloxymethyl)-2-methylbenzoate 

Relevant academic research and scientific papers

Novel S1P1 receptor agonists - Part 4: Alkylaminomethyl substituted aryl head groups

In a previous communication we reported on the discovery of alkylamino pyridine derivatives (e.g. 1) as a new class of potent, selective and efficacious S1P1 receptor (S1PR1) agonists. However, more detailed profiling revealed that this compound class is phototoxic in vitro. Here we describe a new class of potent S1PR1 agonists wherein the exocyclic nitrogen was moved away from the pyridine ring (e.g. 11c). Further structural modifications led to the identification of novel alkylaminomethyl substituted phenyl and thienyl derivatives as potent S1PR1 agonists. These new alkylaminomethyl aryl compounds showed no phototoxic potential. Based on their in vivo efficacy and ability to penetrate the brain, the 5-alkyl-aminomethyl thiophenes appeared to be the most interesting class. Potent and selective S1PR1 agonist 20e, for instance, maximally reduced the blood lymphocyte count (LC) for 24 h after oral administration of 10 mg/kg to rat and its brain concentrations reached >500 ng/g over 24 h.

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Reiterative intramolecular glycosylation supported by a rigid spacer

This paper describes a synthesis of trisaccharide 1 by reiterative intramolecular glycosidation with 5-(bromomethyl)-2-methylbenzoic acid (5a) as starting material for the generation of a rigid spacer. Intramolecular glycosidation of donor-acceptor-tethered compound 24 yielded disaccharide 25. Transesterification of 25 afforded 26, which generated a new linking centre for the next spacer. Repetition of the previous cycle on 26 yielded trisaccharide 1, which again presents an extension point for the synthesis of higher saccharides. Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2003.

A new base mediated method for the cleavage of tert-butyl esters

A new method for the cleavage of tert-butyl esters with NaH in DMF is described.